Explain this page
Arphra AIPlain-English read on Aktis Oncology, Inc.’s valuation06-11today
- Aktis Oncology: Mini-Proteins With A Targeted Punch5d
- Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 202636d
- Aktis Oncology to Present at the BofA Securities Health Care Conference41d
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)43d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$0.72
-96.84% vs spot
Recommendation
Sell
3 of 4 methods
Method spread
0bull3bear
±5% threshold
Analyst PT consensus: $35.33 (+56.12%)
Candlestick · 1Y
Open in chart workstation →AKTS
20.69-5.87%H 23.46L 14.72MA50 18.88MA200 —Avg vol 312K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.38% | +21.15% | +15.75% | +14.47% | +1.03% | +1.03% | +1.03% | +1.03% | +1.03% | +1.03% | +1.03% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$23.20
Bid
$22.00
2 sh
Ask
$24.00
200 sh
Spread
$2.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $1.87M | -$15.14M | $-0.28 |
| Q4 Dec 2024 | $933K | -$12.06M | $-0.23 |
Sector & industry today
LiveSectors
- Consumer Defensive+0.72%
- Technology+0.67%
- Real Estate+0.47%
- Energy+0.45%
- Industrials-0.32%
- Financial Services-0.45%
- Utilities-0.49%
- Healthcare-0.92%
- Consumer Cyclical-0.94%
- Basic Materials-1.06%
- Communication Services-1.12%
Top industries (issuer's industry highlighted)
- Biotechnology-0.05%
- Broadcasting-4.30%
- Coal+3.67%
- Hardware, Equipment & Parts-3.62%
- Real Estate - Development-3.31%
- Trucking-3.16%
- Copper-3.02%
- Apparel - Manufacturers-2.63%
- Medical - Equipment & Services-2.31%
- Oil & Gas Energy+2.28%
- Conglomerates-2.28%
- Auto - Dealerships-2.28%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Aktis Oncology: Mini-Proteins With A Targeted Punchseekingalpha.com·Jun 11, 2026
- Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026globenewswire.com·May 11, 2026
- Aktis Oncology to Present at the BofA Securities Health Care Conferenceglobenewswire.com·May 06, 2026
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)globenewswire.com·May 04, 2026
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)globenewswire.com·May 04, 2026
Recent analyst activity
DB- Jun 02, 2026GradeBuy → BuyAktis Oncology price target raised to $35 from $33 at H.C. WainwrightH.C. Wainwright
- Jun 02, 2026PT$35.00Aktis Oncology price target raised to $35 from $33 at H.C. WainwrightH.C. Wainwright
Peers
No peer list available for AKTS.
Total assets
$264.89M
Total debt
$11.55M
Cash & equiv
$37.78M
Operating CF
-$64.13M
Free cash flow
-$73.71M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $6.5M | -$74.68M | -$63.73M | $-1.19 | -980.93% |
| FY 2024 | $1.49M | -$52.05M | -$43.98M | $-1.26 | -2957.63% |
| FY 2023 | $0 | -$34.79M | -$28.64M | $-0.82 | — |
| FY 2022 | $0 | -$19.76M | -$17.93M | $-0.51 | — |